ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4676-4686

  Kovjazin, Riva ^a   Volovitz, Ilan ^b   Kundel, Yulia ^c   Rosenbaum, Eli ^c   Medalia, Gal ^c   Horn, Galit ^d   Smorodinsky, Nechama I ^d   Brenner, Baruch ^c,d   Carmona, Lior ^a  

^a Vaxil BioTherapeutics Ltd   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer vaccine; MHC class I; MHC class II; MUC1; Signal peptide

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; IMMUCIN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 1; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VXL 100;

ADULT; AGED; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING COMPETITION; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; CAUCASIAN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; INOCULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 79960644754     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.103     Document Type: Article

References (75)

1. Kedar E, Klein E. Cancer immunotherapy: are the results discouraging? Can they be improved? Adv Cancer Res 1992;59:245-322.
2. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805-18.
3. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-32.
4. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8:351-60.
5. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998;59:1-14.
6. Fikes JD, Sette A. Design of multi-epitope, analogue-based cancer vaccines. Expert Opin Biol Ther 2003;3:985-93.
7. Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008;26:4418-25.
8. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T cell tolerance induction. Proc Natl Acad Sci U S A 1996;93:7855-60.
9. Diethelm-Okita BM, Okita DK, Banaszak L, Conti-Fine BM. Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins. J Infect Dis 2000;181:1001-9.
10. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999;22:431-40.
11. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
12. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-26.
13. van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol 2004;173:6753-9.
14. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997;185:2043-51.
15. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-3.
16. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T cell immunity in cancer patients. J Clin Invest 2001;107:477-84.
17. Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997;72:784-90.
18. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007;104:12837-42.
19. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, et al. Induction of tumor-specific CD4+ and CD8+ T cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008;14:178-87.
20. Kovjazin R, Volovitz I, Daon Y, Vider-Shalit T, Carmon L, Louzoun Y. Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: implications for vaccine development. Mol Immunol 2011;48:1009-18.
21. Lyko F, Martoglio B, Jungnickel B, Rapoport TA, Dobberstein B. Signal sequence processing in rough microsomes. J Biol Chem 1995;270:19873-8.
22. Martoglio B. Intramembrane proteolysis and post-targeting functions of signal peptides. Biochem Soc Trans 2003;31:1243-7.
23. Martoglio B, Dobberstein B. Signal sequences: more than just greasy peptides. Trends Cell Biol 1998;8:410-5.
24. Graham RA, Burchell JM, Taylor-Papadimitriou J. The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 1996;42:71-80.
25. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
26. Hareuveni M, Tsarfaty I, Zaretsky J, Kotkes P, Horev J, Zrihan S, et al. A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue. Eur J Biochem 1990;189:475-86.
27. McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995;26:432-9.
28. Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res 2008;68:2419-26.
29. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 2010;201:102-10.
30. Magarian-Blander J, Domenech N, Finn OJ. Specific and effective T cell recognition of cells transfected with a truncated human mucin cDNA. Ann N Y Acad Sci 1993;690:231-43.
31. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T cell proliferation, which is reversible by IL-2. Nat Med 1998;4:43-9.
32. Fung PY, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 1991;51:1170-6.
33. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief CJ, et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993;151:767-76.
34. Stepensky D, Tzehoval E, Vadai E, Eisenbach L. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 2006;143:139-49.
35. Correa I, Plunkett T, Coleman J, Galani E, Windmill E, Burchell JM, et al. Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. Int J Cancer 2005;115:760-8.
36. Carmon L, El-Shami KM, Paz A, Pascolo S, Tzehoval E, Tirosh B, et al. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/-x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLAA2.1/ Db-beta2 microglobulin single chain. Int J Cancer 2000;85:391-7.
37. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, et al. Identification of HLA-A2-restricted T cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-17.
38. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptidepulsed dendritic cells. Blood 2000;96:3102-8.
39. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49-57 [discussion 58].
40. Sangha R, North S. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opin Biol Ther 2007;7:1723-30.
41. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
42. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001;17:1236-7.
43. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, et al. The immune epitope database 2.0. Nucleic Acids Res 2010;38:D854-862.
44. Shimizu Y, DeMars R. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J Immunol 1989;142:3320-8.
45. Herbert LM, Grosso JF, Dorsey Jr M, Fu T, Keydar I, Cejas MA, et al. A unique mucin immunoenhancing peptide with antitumor properties. Cancer Res 2004;64:8077-84.
46. Keydar I, Chou CS, Hareuveni M, Tsarfaty I, Sahar E, Selzer G, et al. Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens. Proc Natl Acad Sci U S A 1989;86:1362-6.
47. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.
48. Smith SH, Brown MH, Rowe D, Callard RE, Beverley PC. Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1. Immunology 1986;58:63-70.
49. Akbar AN, Terry L, Timms A, Beverley PC, Janossy G. Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J Immunol 1988;140:2171-8.
50. Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat 2003;81:195-207.
51. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996;19:59-68.
52. Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Preimmunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996;42:303-9.
53. Schultes BC, Whiteside TL. Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay. J Immunol Methods 2003;279:1-15.
54. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003;4:835-42.
55. Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;26:3426-33.
56. Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, et al. T cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 2002;8:967-72.
57. Horn G, Gaziel A, Wreschner DH, Smorodinsky NI, Ehrlich M. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res 2009;315:1490-504.
58. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
59. Carmon L, Bobilev-Priel I, Brenner B, Bobilev D, Paz A, Bar-Haim E, et al. Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice. J Clin Invest 2002;110:453-62.
60. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989;7:601-24.
61. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
62. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000;164:562-5.
63. Barker CJ, Beagley KW, Hafner LM, Timms P. In silico identification and in vivo analysis of a novel T cell antigen from Chlamydia, NrdB. Vaccine 2008;26:1285-96.
64. Fern J, Good MF. Promiscuous malaria peptide epitope stimulates CD45Ra T cells from peripheral blood of nonexposed donors. J Immunol 1992;148:907-13.
65. Jiang C, Magee DM, Ivey FD, Cox RA. Role of signal sequence in vaccineinduced protection against experimental coccidioidomycosis. Infect Immun 2002;70:3539-45.
66. McMurry J, Sbai H, Gennaro ML, Carter EJ, Martin W, De Groot AS. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb) 2005;85:95-105.
67. Tian S, Maile R, Collins EJ, Frelinger JA. CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol 2007;179:2952-60.
68. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998;160:3363-73.
69. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-50.
70. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
71. Minev BR, Chavez FL, Dudouet BM, Mitchell MS. Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1. Eur J Immunol 2000;30:2115-24.
72. Minev BR, McFarland BJ, Spiess PJ, Rosenberg SA, Restifo NP. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T cell responses and prolongs survival of thymoma-bearing mice. Cancer Res 1994;54: 4155-61.
73. Dorfel D, Appel S, Grunebach F, Weck MM, Muller MR, Heine A, et al. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood 2005;105: 3199-205.
74. Weinzierl AO, Rudolf D, Hillen N, Tenzer S, van Endert P, Schild H, et al. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol 2008;38:1503-10.
75. Hardy B, Yampolski I, Kovjazin R, Galli M, Novogrodsky A. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice. Cancer Res 1994;54:5793-6.